Literature DB >> 7791418

Third-generation cephalosporins.

N C Klein1, B A Cunha.   

Abstract

Third-generation cephalosporins are broad-spectrum antimicrobial agents useful in a variety of clinical situations. No one cephalosporin is appropriate for all infectious disease problems. Cefotaxime and ceftizoxime have the best gram-positive coverage of the third-generation agents. Ceftazidime and cefoperazone are the only third-generation drugs that provide antipseudomonal coverage. Ceftriaxone's long half-life allows for once-daily dosing, making ceftriaxone an excellent drug for outpatient antibiotic therapy of community-acquired infections. Ceftriaxone is also useful for the treatment of Lyme disease and sexually transmitted diseases. The third-generation cephalosporins except for cefoperazone penetrate cerebrospinal fluid and are indicated for the treatment of bacterial meningitis. Their proven record of clinical efficacy, favorable pharmacokinetics, and low frequency of adverse effects make third-generation cephalosporins the preferred antibiotic in many clinical situations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7791418     DOI: 10.1016/s0025-7125(16)30034-7

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  25 in total

1.  Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children.

Authors:  M D Reed; T S Yamashita; C K Knupp; J M Veazey; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Seyedmojtaba Seyedmousavi; Claudia M Lagarde; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  Assessment of Treatment of Community Acquired Severe Pneumonia by Two Different Antibiotics.

Authors:  Karimeldin Ma Salih; Jalal Ali Bilal; Widad Eldouch; Ali Abdin
Journal:  J Clin Diagn Res       Date:  2016-05-01

4.  A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM.

Authors:  JoonHo Lee; Roberto Romero; Sun Min Kim; Piya Chaemsaithong; Chan-Wook Park; Joong Shin Park; Jong Kwan Jun; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2015-09-16

5.  Association between treatment with oral third-generation cephalosporin antibiotics and mortality outcomes in Ebola virus disease: a multinational retrospective cohort study.

Authors:  Adam R Aluisio; Shiromi M Perera; Derrick Yam; Stephanie Garbern; Jillian L Peters; Logan Abel; Daniel K Cho; Dayan Woldemichael; Stephen B Kennedy; Moses Massaquoi; Foday Sahr; Tao Liu; Adam C Levine
Journal:  Trop Med Int Health       Date:  2020-01-22       Impact factor: 2.622

6.  Identification and Characterization of Cefazolin-Induced Liver Injury.

Authors:  Saleh A Alqahtani; David E Kleiner; Marwan Ghabril; Jiezhun Gu; Jay H Hoofnagle; Don C Rockey
Journal:  Clin Gastroenterol Hepatol       Date:  2014-12-18       Impact factor: 11.382

Review 7.  Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use.

Authors:  E Strehl; F Kees
Journal:  Drugs       Date:  2000       Impact factor: 9.546

8.  Cefoperazone Induced Gastrointestinal Bleeding.

Authors:  Goutham Reddy Katukuri; Raja Naga Mahesh Maddala; Kusugodlu Ramamoorthi; Manjunatha Hande
Journal:  J Clin Diagn Res       Date:  2016-08-01

9.  Persistence of Borrelia burgdorferi following antibiotic treatment in mice.

Authors:  Emir Hodzic; Sunlian Feng; Kevin Holden; Kimberly J Freet; Stephen W Barthold
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

10.  A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM.

Authors:  JoonHo Lee; Roberto Romero; Sun Min Kim; Piya Chaemsaithong; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2015-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.